Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Affiliations

¹ Eisai Inc., Woodcliff Lake, NJ, USA.
² Eisai Ltd., Hatfield, UK.
³ BioArctic AB, Warfvinges väg 35, SE-112 51, Stockholm, Sweden.
⁴ Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
⁵ Berry Consultants, LLC, Austin, TX, USA.
⁶ Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA. jcummings@cnsinnovations.com.

Published Erratum

Chad J Swanson et al. Alzheimers Res Ther. 2022.

. 2022 May 21;14(1):70.

doi: 10.1186/s13195-022-00995-9.

¹ Eisai Inc., Woodcliff Lake, NJ, USA.
² Eisai Ltd., Hatfield, UK.
³ BioArctic AB, Warfvinges väg 35, SE-112 51, Stockholm, Sweden.
⁴ Department of Public Health/Geriatrics, Uppsala University, Uppsala, Sweden.
⁵ Berry Consultants, LLC, Austin, TX, USA.
⁶ Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA. jcummings@cnsinnovations.com.

No abstract available

Erratum for

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. Swanson CJ, et al. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. Alzheimers Res Ther. 2021. PMID: 33865446 Free PMC article. Clinical Trial.

1. Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alz Res Therapy. 2021;13:80. doi: 10.1186/s13195-021-00813-8. - DOI - PMC - PubMed